Teacher Retirement System of Texas Takes Position in Spyre Therapeutics, Inc. (NASDAQ:SYRE)

Teacher Retirement System of Texas bought a new position in shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,383 shares of the company’s stock, valued at approximately $242,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Intech Investment Management LLC purchased a new stake in Spyre Therapeutics during the 3rd quarter worth approximately $246,000. Charles Schwab Investment Management Inc. boosted its stake in shares of Spyre Therapeutics by 239.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 333,275 shares of the company’s stock worth $9,802,000 after acquiring an additional 235,094 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Spyre Therapeutics by 15.0% during the third quarter. The Manufacturers Life Insurance Company now owns 43,460 shares of the company’s stock worth $1,278,000 after purchasing an additional 5,678 shares in the last quarter. FMR LLC raised its stake in Spyre Therapeutics by 1.5% in the 3rd quarter. FMR LLC now owns 7,623,881 shares of the company’s stock valued at $224,218,000 after purchasing an additional 115,898 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its holdings in Spyre Therapeutics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 20,132 shares of the company’s stock valued at $592,000 after purchasing an additional 11,344 shares in the last quarter. 80.39% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently issued reports on SYRE. Wolfe Research started coverage on shares of Spyre Therapeutics in a report on Tuesday, March 18th. They set an “outperform” rating and a $27.00 target price for the company. The Goldman Sachs Group upgraded shares of Spyre Therapeutics to a “strong-buy” rating in a research report on Tuesday, February 18th. Finally, Wedbush reissued an “outperform” rating and issued a $65.00 price target on shares of Spyre Therapeutics in a research note on Monday, January 13th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $50.33.

Spyre Therapeutics Trading Down 5.2 %

Shares of SYRE opened at $15.30 on Wednesday. The company’s 50-day moving average price is $20.31 and its 200 day moving average price is $25.37. The firm has a market cap of $921.93 million, a P/E ratio of -2.05 and a beta of 2.98. Spyre Therapeutics, Inc. has a 12-month low of $15.24 and a 12-month high of $40.84.

Spyre Therapeutics (NASDAQ:SYRE) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.89) by $0.08. Equities research analysts forecast that Spyre Therapeutics, Inc. will post -4.46 earnings per share for the current year.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc, a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease).